Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$5.09 USD

5.09
264,873

-0.19 (-3.60%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.

Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS

by Zacks Equity Research

Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

by Zacks Equity Research

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance

by Zacks Equity Research

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

by Zacks Equity Research

Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.

Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug

by Zacks Equity Research

Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

by Zacks Equity Research

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

by Zacks Equity Research

Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.

Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Agenus (AGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 2.59% and 10.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -4.76% and 2.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -33.33% and 94.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

by Zacks Equity Research

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -9.09% and 59.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Philips (PHG) Showcases New AI-Based Solutions at the RSNA

by Zacks Equity Research

Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -142.98% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed at $2.51 in the latest trading session, marking a -1.57% move from the prior day.

Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.

Agenus (AGEN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Agenus (AGEN) closed at $2.63, marking a +0.77% move from the previous day.

Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed the most recent trading day at $2.61, moving -1.14% from the previous trading session.

Agenus (AGEN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Agenus (AGEN) closed at $2.72 in the latest trading session, marking a +1.49% move from the prior day.